Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland - Seite 2
«Prostate.Carcinoma.ai» was certified as a Class IIa medical device in the European Economic Area (EEA) by the notified body BSI Group in December 2023. Switzerland accepts the CE marking for medical devices according to EU MDR 2017/745. The solution integrates seamlessly into existing PACS systems or is available as an on-premise solution and can be provided on the data protection-compliant Swiss Open Telekom Cloud by T-Systems. This partnership combines the comprehensive industry and technology expertise of both companies and offers significant added value to healthcare facilities.
The cooperation between FUSE-AI and T-Systems is just the beginning of a series of developments of AI-supported diagnostic assistance software solutions for various medical indications. Xlife Sciences sees this partnership as a significant contribution to continuing its mission to bridge the gap between innovations and the needs of the healthcare market.
Lesen Sie auch
Financial calendar
Annual Report 2023 | 23 April 2024 |
Annual Shareholders Meeting 2024 | 20 June 2024 |
Half-Year Report 2024 | 19 September 2024 |
Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch
Xlife Sciences AG
Talacker 35
8001 Zurich
Switzerland
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch,
Commercial Register Zurich CHE-330.279.788
Stock Exchange: SIX Swiss Exchange
About Xlife Sciences AG (SIX: XLS)
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research
institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to
healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial
intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch